Brimblecombe, K.R. et al. (2023) Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson’s.
Stephanie J Cragg, Katherine Brimblecombe
Published: 2023-06-09 DOI: 10.17504/protocols.io.4r3l27dxxg1y/v1
Abstract
This collection contains three protocols detailing methods used in Brimblecombe, K.R. et al. (2023) Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson’s .